CDC director nominee Erica Schwartz faces Senate for confirmation hearing

Dr. Erica Schwartz will sit before senators on Wednesday morning as President Trump's choice to lead the Centers for Disease Control and Prevention, opening a confirmation process that will test whether she can win support for the post amid ongoing turmoil at the agency. The hearing marks Schwartz's first appearance in the spotlight since she was tapped for the job in mid-April, and it gives lawmakers their first real chance to press her on how she would run the CDC and whether she has the background the role demands.

Members of the Senate Health, Education, Labor and Pensions committee are expected to question her on her priorities and credentials, a standard step before any floor vote on her nomination. How she handles that scrutiny could shape momentum for her confirmation in the months ahead.

Notably, Schwartz is not the administration's first pick for the job this term — she is the third person Trump has put forward to run the CDC since returning to office. That pattern reflects a broader struggle: the agency has largely gone without a Senate-confirmed, permanent leader for most of his second term, leaving key decisions in the hands of acting officials for extended stretches.

Should she clear the committee and win full Senate approval, Schwartz would inherit an agency under considerable strain. The CDC has been contending with depleted staffing and thinned-out leadership ranks, the product of budget pressures, departures and reorganization efforts that have rippled through the public health workforce in recent years.

Beyond staffing troubles, Schwartz would also be stepping into a CDC that now operates under heightened political oversight compared with years past. New layers of review tied to the administration's broader push to reshape federal health policy have added scrutiny to decisions that were once left largely to career scientists and agency officials, a shift that has drawn concern from some public health veterans who argue it risks politicizing routine scientific judgments.

The stakes of the appointment extend well past Washington. The CDC sets national guidance on everything from vaccine schedules and outbreak response to chronic disease prevention, meaning prolonged leadership gaps or a contentious confirmation fight could slow the agency's ability to respond decisively to emerging health threats. State and local health departments, which often look to the CDC for direction during outbreaks, have felt the effects of that uncertainty as the top job has churned.

Senators from both parties are likely to use Wednesday's session to probe not only Schwartz's qualifications but also her independence — specifically, whether she would resist political pressure on scientific decisions if confirmed. Given the fate of the administration's two earlier nominees, her answers on that question may prove decisive in determining whether her nomination advances or stalls like those before it.

No timeline has been set for when the committee might vote on advancing her nomination to the full Senate, and confirmation is not guaranteed. For now, Wednesday's hearing represents the first concrete test of whether Trump's latest attempt to fill the CDC's top post will succeed where two previous efforts have not.

Source: NPR Health